Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Sell
28
AIMI Quote, Financials, Valuation and Earnings
Last price:
$0.08
Seasonality move
:
-0.92%
Day range:
$0.08 - $0.08
52-week range:
$0.03 - $0.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
32.28x
P/B ratio:
--
Volume:
16.2K
Avg. volume:
225.9K
1-year change:
-78.79%
Market cap:
$5.9M
Revenue:
$170K
EPS (TTM):
-$0.24
Analysts' Opinion
-
Consensus RatingAIM ImmunoTech has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.50, AIM ImmunoTech has an estimated upside of 1848.05% from its current price of $0.08.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.08.
Fair Value
-
According to the consensus of 1 analyst, AIM ImmunoTech has 1848.05% upside to fair value with a price target of $1.50 per share.
AIMI vs. S&P 500
-
Over the past 5 trading days, AIM ImmunoTech has underperformed the S&P 500 by -11.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
AIM ImmunoTech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AIM ImmunoTech revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter AIM ImmunoTech reported revenues of $16K.
Earnings Growth
-
AIM ImmunoTech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter AIM ImmunoTech reported earnings per share of -$0.05.
Enterprise value:
5.6M
EV / Invested capital:
-2.93x
Price / LTM sales:
32.28x
EV / EBIT:
--
EV / Revenue:
38.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.43x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$113K
Return On Assets:
-126%
Net Income Margin (TTM):
-10416.44%
Return On Equity:
-877.96%
Return On Invested Capital:
-364.53%
Operating Margin:
-22618.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $156K | $193K | $146K | $40K | $16K | |
| Gross Profit | $87K | $143K | $113K | $32K | $6K | |
| Operating Income | -$21.1M | -$33.4M | -$17.7M | -$5.7M | -$3.6M | |
| EBITDA | -$20.3M | -$30.8M | -$14.3M | -$5.7M | -$3.5M | |
| Diluted EPS | -$0.40 | -$0.64 | -$0.24 | -$0.12 | -$0.05 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $51.2M | $50.4M | $33.2M | $11.3M | $2.6M | |
| Total Assets | $74.1M | $54.2M | $37.5M | $16.2M | $6.2M | |
| Current Liabilities | $970K | $766K | $1.8M | $9.9M | $9.8M | |
| Total Liabilities | $3.1M | $854K | $2.5M | $11.4M | $10.1M | |
| Total Equity | $71M | $53.3M | $35M | $4.8M | -$3.9M | |
| Total Debt | $234K | -- | -- | $2.6M | $2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$17M | -$22.4M | -$12.4M | -$4.8M | -$2.4M | |
| Cash From Investing | $11.3M | -$912K | $5.8M | -$158K | $898K | |
| Cash From Financing | $180K | $3.2M | $4.3M | $2.8M | $660K | |
| Free Cash Flow | -$17.3M | -$23M | -$13M | -$4.9M | -$2.4M | |
AIMI
Sector
Market Cap
$5.9M
$33.4M
Price % of 52-Week High
16.42%
45.16%
Dividend Yield
0%
0%
Shareholder Yield
-18.24%
-0.66%
1-Year Price Total Return
-78.79%
-40%
Beta (5-Year)
0.944
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.08
200-day SMA
Sell
Level
$0.19
Bollinger Bands (100)
Sell
Level
0.07 - 0.17
Chaikin Money Flow
Sell
Level
-576.2M
20-day SMA
Sell
Level
$0.09
Relative Strength Index (RSI14)
Sell
Level
43.85
ADX Line
Buy
Level
44.04
Williams %R
Buy
Level
-93.1741
50-day SMA
Sell
Level
$0.08
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
619.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-75.778)
Sell
CA Score
(Annual)
Level (-6.6857)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (14.0327)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Stock Forecast FAQ
In the current month, AIMI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AIMI average analyst price target in the past 3 months is $1.50.
-
Where Will AIM ImmunoTech Stock Be In 1 Year?
According to analysts, the consensus estimate is that AIM ImmunoTech share price will rise to $1.50 per share over the next 12 months.
-
What Do Analysts Say About AIM ImmunoTech?
Analysts are divided on their view about AIM ImmunoTech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AIM ImmunoTech is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is AIM ImmunoTech's Price Target?
The price target for AIM ImmunoTech over the next 1-year time period is forecast to be $1.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AIMI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AIM ImmunoTech is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of AIMI?
You can purchase shares of AIM ImmunoTech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AIM ImmunoTech shares.
-
What Is The AIM ImmunoTech Share Price Today?
AIM ImmunoTech was last trading at $0.08 per share. This represents the most recent stock quote for AIM ImmunoTech. Yesterday, AIM ImmunoTech closed at $0.08 per share.
-
How To Buy AIM ImmunoTech Stock Online?
In order to purchase AIM ImmunoTech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for Jun 2
Regeneron Pharmaceuticals [REGN] is down 0.3% over the past day.
Buy
55
RGC alert for Jun 2
Regencell Bioscience Holdings [RGC] is down 7.07% over the past day.
Sell
42
AMBA alert for Jun 2
Ambarella [AMBA] is down 1.33% over the past day.
